Skip navigation

Strong collaborations are key to driving progress.

Join Our Family of Partners!

We are constantly adding new partners from Government, Healthcare, Industry, Academic, and Patient Advocacy. We have fostered many relationships with collaborators who share our goals of bringing innovative healthcare solutions to patients and healthcare professionals. Some of our partners have been an important part of our history.

We are always looking for new partners to join with us to discover, clinical trial and commercialize new therapeutics and diagnostics utilizing our NAi Interrogative Biology® platform. We specialize in oncology, neurology and rare disease. Work with us!

Check out many of our current partners below.  This list is by no means exhaustive; however, it includes many of our current partners.

Walter Reed National Marine Medical Center (WRNMMC)

BPGbio has partnered with WRNMMC through a CRADA to development novel diagnostics for prostate cancer and innovative diagnostics and therapies for breast cancer using BPGbio’s precision medicine AI and OMICs capabilities.

DOD: Center For Prostate Disease Research (CPDR)

BPGbio have partnered with the DOD: CPDR in the optimization of BPGbio’s prostate cancer diagnostics kit.

U.S. Department of Veterans Affairs

BPGbio works extensively with the US Department of Veteran Affairs to tackle diagnostic and therapeutic challenges associated with prostate cancer treatment and diagnosis.

Advent Health

BPGbio works with Advent Health utilizing artificial intelligence to tackle major healthcare challenges associated with COVID-19 as well as metabolic diseases.


In 2022 BPGbio had signed an agreement with Microsoft for the use of Microsoft’s cloud services (Azure) to launch BPGbio’s Intelligent Interrogative Biology® platform software as a SaaS model. The goal is to harness data from industrial partner and use BPGbio’s proprietary biology discovery tools and aid client’s needs in the areas of novel targets and biomarker discovery. Several potential clients have been identified and initial contact has been made.

University of Tennessee and ORNL

BPGbio has partnered with University of Tennessee and ORNL to utilized Bayesian Artificial Intelligence to identify novel targets and therapeutic strategies for COVID-19 and cancer. In addition, BPGbio is currently engaging University of Tennessee and Oak Ridge National Laboratory (ORNL) through a sponsored research agreement and is focused on use of computational tools for supporting the Hit Identification phase of Drug Discovery. UoT/ORNL provides the scale for performing computation screening across several targets of interest to BPGbio.

Joslin Diabetes Center

BPGbio collaborates with Joslin Diabetes Center to identify novel molecular drivers of metabolic diseases.

Mount Sinai School of Medicine

BPGbio works closely with Mount Sinai School of Medicine through the use of artificial intelligence and omics technologies to identify novel drivers of neurodegenerative diseases.

Stanford University School of Medicine

BPGbio collaborates with Stanford University to evaluate its therapeutics for the treatment of Glioblastoma.

DUKE University

BPGbio is closely working with DUKE University to investigate biochemical properties of the E2 conjugating enzyme UBE2K.

University of Oxford

BPGbio plans to establish future collaborations with the University of Oxford, through collaborative and Sponsored Research Agreement. The key focal points of the collaboration include support for Target Biology, Target Disease Linkage, Med chem, Assay Development and Structural Biology. Oxford University provides the critical expertise and excess R&D capacity that is required for BPGbio’s R&D expansion.

University of Miami

BPGbio has CRADA’s with two key institutions University of Miami and Mount Sinai School of Medicine for the past several years to include multiple projects.

AFFPC (Alliance of Families Fighting Pancreatic Cancer)

BPGbio collaborated with AFFPC to advance novel biomarkers for detection of Pancreatic Cancer.


BPGbio partnered with debra for patient advocacy in patients suffering with EB (Epidermolysis Bullosa). BPGbio is working on a therapeutic for EB (Epidermolysis Bullosa). BPGbio’s therapeutic, BPM31510, is in clinical trials and has FDA Orphan-Drug Designation for the treatment of patients with Epidermolysis Bullosa.

Sanofi Pasteur

Sanofi Pasteur (SP) has sought to identify biomarkers of breadth, durability and antibody response to the licensed influenza annual vaccine Fluzone™. Towards this end, SP took advantage of BPGbio proprietary Intelligent Interrogative Biology® platform in order to augment the clinical, genetic and serological data with multi-omic entities as potential biomarkers for the aforementioned vaccination outcomes.

Boehringer Ingelheim (BI)

Boehringer Ingelheim (BI) has sponsored a project with BPGbio to identify biomarkers for Crohn’s Disease, Ulcerative Colitis and Systemic Sclerosis. Towards this end, BPGbio’s Intelligent Interrogative Biology® platform augmented the clinical and transcriptomic data with serum proteomic entities for the aforementioned diseases. Following data collection, the BPGbio AI technology was employed, which uses unbiased and data-driven methods proven to find cause-and-effect relationships in low and high-dimensional molecular datasets. The causal networks generated by BPGbio AI were further analysed to identify candidate biomarkers for Crohn’s Disease, Ulcerative Colitis and Systemic sclerosis.


BPGbio and AZ signed a collaborative early drug discovery agreement for identification of Hit molecule for a new target for Parkinson’s Disease identified by the BPGbio intelligent Interrogative Biology® Platform. AZ provided BPGbio with their fully annotated Fragment library that was selected for ease of Hit to Lead and Lead Op transition once the program was nominated for further progression.